Cancer Therapy

Report: Taxotere offers significant benefits for head and neck cancer patients

Published in Clinical Oncology Week, July 5th, 2004

The European Organization for Research and Treatment of Cancer (EORTC) announced results from its phase III trial that the addition of Taxotere (docetaxel) Injection Concentrate to a standard therapy for nonresectable, locally advanced, squamous cell carcinoma of the head and neck allows patients to live longer.

The data, presented at the annual meeting of the American Society of Clinical Oncology in New Orleans, Louisiana, demonstrates that in addition to superior overall survival rates, patients also benefited from significantly improved progression-free survival and cancer response rates, as well as a lower rate of severe side effects compared to the standard...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Clinical Oncology Week

Source: Clinical Oncology Week (2004-07-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry